Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus recommendation of “Hold” from the five research firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $13.75.

A number of brokerages recently weighed in on TBPH. TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $15.00 to $10.00 in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Monday, September 16th. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th.

Insider Activity

In other news, major shareholder Eli Samaha bought 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares in the company, valued at $74,186,970. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Kennedy Capital Management LLC increased its stake in Theravance Biopharma by 3.7% in the 1st quarter. Kennedy Capital Management LLC now owns 38,202 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 1,359 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Theravance Biopharma by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock worth $444,000 after buying an additional 3,532 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 4,990 shares during the period. American Century Companies Inc. increased its stake in Theravance Biopharma by 11.7% in the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 6,026 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Theravance Biopharma by 16.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after acquiring an additional 7,509 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Trading Up 1.6 %

Theravance Biopharma stock opened at $8.80 on Friday. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.71. The firm has a market capitalization of $430.50 million, a price-to-earnings ratio of -9.57 and a beta of 0.25. The firm has a 50 day moving average of $8.20 and a 200 day moving average of $8.76.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. During the same period last year, the company earned ($0.28) EPS. On average, analysts predict that Theravance Biopharma will post -1.04 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.